サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1577591

海洋医薬品の世界市場

Marine Pharmaceuticals

出版日
ページ情報
英文 133 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
海洋医薬品の世界市場
出版日: 2024年10月25日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 133 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

海洋医薬品の世界市場は2030年までに69億米ドルに達する見込み

2023年に41億米ドルと推定される海洋医薬品の世界市場は、分析期間2023-2030年にCAGR 7.6%で成長し、2030年には69億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるオンコロジーエンドユースは、CAGR 8.1％を記録し、分析期間終了時には33億米ドルに達すると予測されます。心血管エンドユーズ分野の成長率は、分析期間中CAGR 7.5%と推定されます。

米国市場は11億米ドルと推定、中国はCAGR 7.3％で成長予測

米国の海洋医薬品市場は2023年に11億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに11億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは7.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.0％と6.4％と予測されています。欧州では、ドイツがCAGR約6.0％で成長すると予測されています。

世界の海洋医薬品市場- 主要動向と促進要因のまとめ

海洋医薬品とは何か、なぜ現代医療で重要なのか？

海洋医薬品とは、藻類、海綿動物、軟体動物、バクテリアなどの海洋生物に由来する医薬品や治療化合物を指します。これらの化合物はユニークな化学構造と生物学的活性を有しており、がん、炎症、感染症など幅広い疾患の治療に有用です。海洋環境、特に深海噴出孔やサンゴ礁のような極限環境は、新規薬剤候補としての可能性を秘めた生物活性物質の宝庫となっています。研究開発者や製薬会社は、より効果的な新しい治療法を求めて、海洋生物に含まれる天然化合物を活用し、独自の作用機序を持つ薬剤を開発するために、海洋の生物多様性の探索をますます進めています。代表的な例としては、慢性疼痛管理に用いられるジコノタイドや抗がん剤のトラベクテジンといった海洋由来の医薬品が挙げられます。海洋資源から新薬を発見する可能性は、バイオテクノロジーや製薬業界において、海洋医薬品を有望かつ急速に発展する分野として位置づけています。

技術の進歩は海洋創薬の可能性をどのように広げているのか？

技術の進歩は、海洋医薬品の発見と開発の可能性を大きく広げました。ゲノミクス、プロテオミクス、メタボロミクスといった最新の技術により、科学者は海洋生物多様性を分子レベルで探索し、生物活性化合物をより効率的に同定・単離できるようになりました。また、深海探査技術や遠隔操作車（ROV）の開発により、研究者はこれまで到達できなかった海洋環境にアクセスできるようになり、ユニークな生化学的特性を持つ新しい生物を発見できる可能性が高まっています。さらに、ハイスループット・スクリーニングとバイオプロスペクティングの進歩により、海洋生物からの医薬品候補の同定が加速しています。また、合成生物学と生物工学の革新は、製薬会社が実験室内で海洋化合物を再現し、天然の海洋資源を枯渇させることなく持続可能な生産を確保するのに役立っています。このような技術の飛躍的進歩は、海洋医薬品開発の進歩を促し、従来の治療法に抵抗性を示す疾患に対する新たな治療法への扉を開いています。

なぜ持続可能性と規制が海洋医薬品の成長に不可欠なのか？

医薬品開発のための海洋環境の探査は、持続可能性と規制に関する重要な検討事項を提起します。医薬品開発のための海洋生物の採取は、特にサンゴ礁や深海環境のような脆弱な生態系において、生態系に大きな影響を与える可能性があります。その結果、製薬会社や研究者に対し、水産養殖、合成生産、微生物発酵による海洋化合物の調達など、持続可能な方法を採用するよう求める圧力が高まっています。さらに、海洋生物試料の規制は進化しており、各国が領海内での海洋資源の採取をより厳しく規制しています。遺伝資源へのアクセスを規定する名古屋議定書のような国際協定は、海洋医薬品探査をめぐる政策を形成する上で重要な役割を果たしています。企業は、環境への影響を最小限に抑えつつ、倫理的かつ合法的に海洋化合物を取得するために、こうした規制の枠組みをうまく利用しなければならないです。

海洋医薬品の世界市場成長の原動力は？

世界の海洋医薬品市場の成長は、海洋バイオテクノロジーの進歩、研究資金の増加、病気と闘うための新薬に対する需要の高まりなど、いくつかの要因によってもたらされています。特に新しい抗生物質や抗がん剤の探索において、海洋が生物学的に活性な化合物の未開発の供給源であるという認識が高まっていることが、主要な成長要因の一つです。ハイスループット・スクリーニングやバイオインフォマティクスといった創薬技術の進歩により、海洋生物から潜在的な薬剤候補を同定することが容易になっています。また、薬剤耐性疾患の増加や代替療法の必要性も、海洋由来の医薬品への関心を高めています。さらに、学術機関、研究機関、製薬企業間の共同研究の拡大が、この分野での技術革新を加速させています。政府や民間団体は海洋創薬プログラムへの投資を増やしており、市場成長をさらに促進しています。海洋生物多様性の可能性に対する認識が高まるにつれ、海洋医薬品市場は継続的な拡大が見込まれています。

調査対象企業の例（注目の43社）

  • AbbVie, Inc.
  • Aphios Corporation
  • BioMarin Pharmaceutical
  • Cyanotech Corporation
  • GlycoMar Ltd.
  • GSK Plc
  • MARINE LIFESCIENCES
  • Marine Polymer Technologies, Inc.
  • Marinomed Biotech AG
  • Pelagia AS

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP24480

Global Marine Pharmaceuticals Market to Reach US$6.9 Billion by 2030

The global market for Marine Pharmaceuticals estimated at US$4.1 Billion in the year 2023, is expected to reach US$6.9 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2023-2030. Oncology End-Use, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$3.3 Billion by the end of the analysis period. Growth in the Cardiovascular End-Use segment is estimated at 7.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 7.3% CAGR

The Marine Pharmaceuticals market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 7.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.0% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.0% CAGR.

Global Marine Pharmaceuticals Market - Key Trends & Drivers Summarized

What Are Marine Pharmaceuticals, and Why Are They Important in Modern Medicine?

Marine pharmaceuticals refer to drugs and therapeutic compounds derived from marine organisms such as algae, sponges, mollusks, and bacteria. These compounds have unique chemical structures and biological activities that make them valuable for treating a wide range of diseases, including cancer, inflammation, and infectious diseases. Marine environments, particularly extreme habitats like deep-sea vents and coral reefs, have become a treasure trove of bioactive substances that offer potential as novel drug candidates. Researchers and pharmaceutical companies are increasingly exploring the ocean's biodiversity for new, more effective treatments, leveraging the natural compounds found in marine organisms to develop drugs with unique mechanisms of action. Some notable examples include marine-derived drugs like ziconotide, used for chronic pain management, and trabectedin, an anti-cancer agent. The potential for discovering novel drugs from marine resources has positioned marine pharmaceuticals as a promising and rapidly evolving field within the biotechnology and pharmaceutical industries.

How Are Technological Advancements Expanding Opportunities in Marine Drug Discovery?

Technological advancements have significantly expanded the possibilities for discovering and developing marine pharmaceuticals. Modern techniques like genomics, proteomics, and metabolomics allow scientists to explore marine biodiversity at a molecular level, identifying and isolating bioactive compounds more efficiently. The development of deep-sea exploration technology and remote-operated vehicles (ROVs) has also enabled researchers to access previously unreachable marine environments, increasing the potential for finding new organisms with unique biochemical properties. Furthermore, advancements in high-throughput screening and bioprospecting have accelerated the identification of drug candidates from marine organisms. Innovations in synthetic biology and bioengineering are also helping pharmaceutical companies recreate marine compounds in the laboratory, ensuring sustainable production without depleting natural marine resources. These technological breakthroughs are driving progress in marine drug development, opening the door to new treatments for diseases that are resistant to traditional therapies.

Why Are Sustainability and Regulation Crucial to the Growth of Marine Pharmaceuticals?

The exploration of marine environments for pharmaceutical development raises important sustainability and regulatory considerations. Harvesting marine organisms for drug development can have significant ecological impacts, particularly in fragile ecosystems such as coral reefs or deep-sea environments. As a result, there is increasing pressure on pharmaceutical companies and researchers to adopt sustainable practices, such as sourcing marine compounds through aquaculture, synthetic production, or microbial fermentation. Additionally, the regulation of marine bioprospecting is evolving, with countries enforcing stricter controls on the extraction of marine resources within their territorial waters. International agreements like the Nagoya Protocol, which governs access to genetic resources, are playing a key role in shaping the policies around marine pharmaceutical exploration. Companies must navigate these regulatory frameworks to ensure the ethical and legal acquisition of marine compounds while minimizing their environmental footprint.

What Is Driving the Growth of the Global Marine Pharmaceuticals Market?

The growth in the global marine pharmaceuticals market is driven by several factors, including advances in marine biotechnology, increased research funding, and the rising demand for novel drugs to combat diseases. One key growth driver is the growing recognition of the ocean as an untapped source of biologically active compounds, particularly in the search for new antibiotics and anti-cancer agents. Technological advancements in drug discovery, such as high-throughput screening and bioinformatics, are making it easier to identify potential drug candidates from marine organisms. The increasing prevalence of drug-resistant diseases and the need for alternative therapies are also fueling interest in marine-derived pharmaceuticals. Furthermore, the expansion of collaborative efforts between academic institutions, research organizations, and pharmaceutical companies is accelerating innovation in the field. Governments and private entities are increasing investments in marine drug discovery programs, further driving market growth. As awareness of marine biodiversity’s potential grows, the marine pharmaceuticals market is poised for continued expansion.

Select Competitors (Total 43 Featured) -

  • AbbVie, Inc.
  • Aphios Corporation
  • BioMarin Pharmaceutical
  • Cyanotech Corporation
  • GlycoMar Ltd.
  • GSK Plc
  • MARINE LIFESCIENCES
  • Marine Polymer Technologies, Inc.
  • Marinomed Biotech AG
  • Pelagia AS

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Marine Pharmaceuticals - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Focus on Drug Discovery from Marine Sources Throws Spotlight on the Growing Potential of Marine Pharmaceuticals
    • Rising Prevalence of Drug-Resistant Diseases Spurs Significant Growth in Research for Marine-Derived Antibiotics
    • Technological Advancements in Marine Biotechnology Strengthens the Business Case for Exploring Novel Marine Bioactive Compounds
    • Expansion of Marine Bioprospecting Expands Addressable Market Opportunity for Marine-Based Drug Development
    • Rising Demand for Alternative Cancer Treatments Drives Adoption of Marine-Derived Anticancer Compounds
    • Growing Awareness of Sustainability and Eco-Friendly Sourcing Generates Demand for Sustainable Harvesting of Marine Pharmaceuticals
    • Increasing Use of Marine-Derived Compounds in Chronic Disease Management Propels Growth in Marine Pharmaceuticals
    • Integration of Genomics and Bioinformatics in Marine Drug Discovery Strengthens the Case for More Targeted Drug Development
    • Rising Investment in Marine Biotechnology Research Generates Opportunities for New Therapeutic Agents from Marine Organisms
    • Increased Focus on Marine Ecosystem Conservation Expands the Need for Sustainable Marine Pharmaceutical Practices
    • Growing Demand for Natural and Biocompatible Therapies Propels Market Growth for Marine-Derived Nutraceuticals and Pharmaceuticals
    • Advancements in Extraction and Cultivation Techniques Drive Adoption of Marine Pharmaceuticals by Reducing Production Costs
    • Rising Incidence of Neurological Disorders Expands Research into Marine-Derived Neuroprotective Agents
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Marine Pharmaceuticals Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Marine Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Marine Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Marine Pharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oncology End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oncology End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Oncology End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cardiovascular End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Cardiovascular End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Cardiovascular End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Infectious Diseases End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Infectious Diseases End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Infectious Diseases End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • JAPAN
    • Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CHINA
    • Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: China 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • EUROPE
    • Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Marine Pharmaceuticals by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Marine Pharmaceuticals by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Marine Pharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • FRANCE
    • Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: France 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: UK 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 53: Rest of World Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of World Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of World 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION